Menopause and mental health: mood changes, treatment and getting help

Can menopause affect mood, and can HRT help?

Menopause-associated symptoms can include low mood, anxiety, irritability and disturbed sleep. HRT may help some people, especially when depressive symptoms begin alongside other menopause symptoms. It does not establish that every new mental health problem is hormonal, and it does not replace treatment for suspected or diagnosed depression. NICE explicitly separates these situations: consider HRT for associated depressive symptoms below the threshold of a depression diagnosis, and use both menopause and depression guidance when depression is suspected or diagnosed. [1]

The practical question is what changed, how much it affects your life and which problems need treatment together. Feeling less resilient after repeated night sweats may call for a different plan from persistent hopelessness, panic attacks or loss of interest in almost everything. Both deserve attention. You do not need to identify the cause on your own before asking for help. [1], [2]

A helpful consultation can include menstrual changes, sleep, medicines, previous mood episodes, physical symptoms and current stresses. The aim is a workable care plan, not choosing between “hormones” and “mental health.” If you feel at immediate risk of harming yourself or someone else, seek urgent local emergency or crisis care rather than waiting for a menopause appointment or a hormone adjustment. [2]

Which decision comes first?

These are discussion priorities, not a diagnostic decision tree. More than one row can apply. A clinician may use a validated questionnaire, but the result sits within an assessment of symptoms, functioning, history and safety. A good score on one measure should not erase a concern you explain in words. [1], [2]

How do you describe symptoms without diagnosing yourself?

Start with concrete changes rather than a label: waking distressed, losing pleasure in activities, withdrawing from people, struggling to concentrate or becoming unusually irritable. Explain when they began, whether they persist or vary, and what you can no longer do comfortably. Mention whether low mood predates menstrual changes or has returned after an earlier episode. The same everyday phrase, such as “brain fog,” can mean different experiences that deserve clarification. [2]

Bring your current medicines and supplements, including hormonal contraception, systemic HRT and any recent changes. A clinician can consider medical and medication-related contributors rather than automatically ordering a menopause hormone panel. In people aged 45 or over with typical symptoms, NICE generally identifies menopause clinically; younger ages and other presentations require different consideration. A serum estrogen result is not a test for depression or proof that a particular HRT dose will improve mood. [1]

Describe sleep separately. Are hot flashes waking you, is worry keeping you awake, or do you sleep for hours and still feel unrefreshed? Also explain practical circumstances: caregiving, pain, financial pressure, relationship difficulties or changes at work. Discussing these does not diminish a possible hormonal contribution. It gives the clinician information for treating the whole problem. [1], [2]

You can ask to speak privately, bring a support person if you choose, or give a short written account when speaking is difficult. Choose a few examples that show the effect on daily life rather than trying to produce an exhaustive chart. If a previous appointment felt dismissive, a useful next request is a named follow-up plan: what is being assessed, which treatment is being tried and what would prompt earlier contact.

What does the hormone trial actually show?

A 2018 randomized trial studied 172 initially euthymic women aged 45–60 in the menopause transition or early postmenopause. Over 12 months, clinically significant depressive symptoms occurred in 32.3% of the placebo group and 17.3% of the group receiving transdermal estradiol with intermittent micronized progesterone. The outcome was reaching a specified symptom threshold, CES-D of at least 16, during follow-up. It was not a trial establishing HRT as a substitute for treatment of major depression. [3]

The trial is useful because the groups were randomized. Its boundaries matter too: the participants did not start with the depression the study was trying to prevent, the intervention was a particular research regimen, and stage-related analyses did not show an identical benefit across the entire population. A result over one year does not answer every long-term safety or effectiveness question. The paper's intermittent progesterone schedule is not copied here as a general endometrial-protection prescription. [3]

For a reader, the strongest lesson is to keep the outcome and starting population attached to the result. “Fewer participants crossed a symptom threshold” is more precise than “HRT prevents depression in everyone.” The percentages are study-group observations, not an estimate of your personal probability of improvement. Current guideline recommendations and an individual assessment remain the basis of treatment choices. [1], [3]

Is CBT an alternative or an addition?

Cognitive behavioural therapy, or CBT, is a structured psychological treatment. NICE considers it an option for depressive symptoms associated with vasomotor symptoms and for related sleep problems. It can be used with other treatments, when another option is unsuitable, or when a person prefers it. Being offered CBT should not mean that physical symptoms are being dismissed. [1]

The menopause-specific evidence is not uniformly strong. NICE's rationale reports varying measures and results, with many comparisons showing no difference in depressive symptoms and some showing benefit. It also draws on established CBT evidence for depression more generally. That supports offering a choice without promising that every menopause-specific course will remove anxiety or low mood. The committee did not make a menopause-specific anxiety recommendation from this evidence. That is not a conclusion that ordinary anxiety treatment cannot help. [4]

Ask what the proposed service actually treats. A menopause-focused course addressing hot-flash distress and sleep can differ from therapy for a diagnosed depressive or anxiety disorder. Availability, format, waiting time and personal preference matter. If one service cannot cover both needs, ask how the clinicians will coordinate care rather than assuming you must complete one approach before discussing another. [1], [2]

Do antidepressants and menopause treatment compete?

They can be part of the same plan when each has a clear purpose. NICE's recommendation against routinely using certain antidepressants as first-line treatment for vasomotor symptoms alone does not mean they should be withheld for depression. The indication matters. When depression is suspected or diagnosed, treatment choices depend on clinical assessment, severity, previous response and preferences, alongside menopause care. [1], [2]

Tell the prescriber what has helped before, what was difficult and what you are hoping to improve now. If you already take a mental health medicine, discuss any proposed change with its prescriber rather than stopping because you start HRT or because someone online describes a different experience. Side effects and interactions are product-specific; the names and formulation of every medicine help make that review possible. [2]

A plan should say who is responsible for follow-up and how to get help if symptoms worsen. Depression treatment may need contact earlier than the ordinary menopause treatment review. A clinician may pay particular attention around starting or changing antidepressants, including agitation, anxiety and suicidal thoughts. These concerns require their own clinical response rather than a rule to wait for HRT to “settle.” [2]

What if mood worsens on the HRT regimen?

Report a meaningful deterioration, especially one that affects functioning or safety. Record whether it followed a start, formulation change or change in the estrogen or progestogen schedule, and whether symptoms appear during particular treatment days. The pattern is useful information, but it cannot by itself distinguish a medication effect from changing symptoms, interrupted sleep or another condition. Review the complete regimen with the prescriber. [1], [2]

If you have a uterus and use systemic estrogen, adequate endometrial protection remains necessary. Omitting progesterone or another prescribed progestogen because you suspect it affects mood can leave a different risk untreated. A clinician can review options and their product-specific suitability rather than simply increasing estrogen or removing protection. The general requirement does not identify one universally best-tolerated preparation. [5]

Ask for an explicit plan if a change is proposed: which product changes, which schedule continues, when response will be reviewed and which symptoms require earlier contact. If several things change simultaneously, interpretation becomes harder. You can explain that concern without delaying a necessary safety change. The goal is to maintain effective care while taking your experience seriously.

Is brain fog the same as dementia?

No. Difficulty concentrating or retrieving words is a description of a symptom, not a dementia diagnosis. Explain what happens and whether it is persistent, worsening or affecting safety and daily tasks. An assessment can consider sleep, mood and other causes. Relief of night sweats or better concentration after treatment does not establish that the medicine prevents future dementia. [1], [2]

The WHI Memory Study studied an older population: participants were aged 65 or over, and the combined regimen was oral conjugated equine estrogens with medroxyprogesterone acetate. Its dementia findings cannot be relabeled as a trial of brain fog treatment in a 45-year-old on a patch. Equally, that limitation does not prove that modern HRT prevents dementia. NICE advises against offering HRT for dementia prevention. [1], [6]

See the WHI explanation for the distinction between the trials, ages and outcomes. New progressive cognitive problems deserve clinical attention rather than an online hormone target. A subjective improvement is valuable to you; it remains a different outcome from preventing a diagnosed neurodegenerative disease.

What do public experiences add?

A public Mumsnet discussion refreshed for this guide includes accounts of improved mood on HRT, benefit limited to hot flashes, and unwanted effects that made treatment difficult. People also describe therapy, antidepressants, movement and social connection as parts of their care. The contrast is useful: feeling better in one area does not guarantee that every problem improves, and a difficult response does not invalidate another person's benefit. [7]

These selected posts are not a representative survey or a way to rank treatments. No usernames, identifiable histories, copied doses or supplement routines are included. Some advice in the discussion extends well beyond the evidence; it is not adopted here. The practical themes are asking for recognition, explaining mixed response and keeping more than one treatment option open. [7]

What is useful to track and bring to follow-up?

Choose a small set of observations you can sustain: mood in your own words, sleep interruptions, hot flashes, the treatment actually taken and one measure of daily functioning. For example, “I went to the shops comfortably today” can communicate something a numerical rating misses. Note when a medicine changed and when an unwanted effect began. These are editorial suggestions for preparing a conversation, not a validated depression scale or an instruction to monitor constantly.

Separate observation from interpretation. “Low mood on these dates” is a record; “this proves progesterone causes depression” is a conclusion that needs assessment. Missing entries are acceptable. If recording symptoms increases worry or feels burdensome, shorten the record or use a few dated examples. You can share only what is relevant and comfortable for you.

At follow-up, ask whether the original goals improved, whether a new concern needs a separate assessment and who manages the next step. NICE ordinarily reviews menopause treatment at three months and annually thereafter, but effectiveness concerns, adverse effects and mental health needs can justify earlier review. No routine calendar should postpone help for deterioration or immediate risk. [1], [2]

What questions are worth asking?

Can I ask about HRT if low mood is my main complaint?

Yes, especially if low mood began around other menopause symptoms, but ask for assessment of both mood and menopause. NICE considers HRT for associated depressive symptoms below the threshold of a depression diagnosis. Persistent impairment, loss of interest or safety concerns can need additional care. Bring the timing, sleep pattern, menstrual changes and previous treatment history; the aim is a suitable combined plan rather than proving a hormonal cause yourself. See assessment and depression care. [1], [2]

Does the 2018 trial mean I should take HRT to prevent depression?

It does not establish routine prevention for everyone. The trial involved initially euthymic women and measured crossing a symptom-score threshold over one year. Its particular intervention and stage-related findings limit generalization, and it did not compare HRT with established treatment for major depression. The result can inform a clinical discussion without supplying a personal benefit estimate or a copied regimen. See the trial explanation for the population, percentages and qualifications. [3]

If HRT helps my sleep, should I stop an antidepressant?

Discuss that with the antidepressant prescriber before changing it. Better sleep or fewer hot flashes can be valuable while a medicine still serves a separate depression or anxiety indication. NICE recommends coordinating depression and menopause care when needed; its advice about antidepressants for vasomotor symptoms alone is a different question. Review benefits, unwanted effects and any proposed change together, with a follow-up plan suited to the mental health treatment. See depression care. [1], [2]

Is being offered CBT a sign that my symptoms are being dismissed?

It should be an offered treatment option, not a dismissal of physical symptoms. NICE considers menopause-specific CBT alongside other options or when they are unsuitable or unwanted, including for related depressive symptoms and sleep problems. Ask whether the course addresses hot-flash distress, insomnia, a diagnosed mental health condition or several needs. Evidence and service formats differ, so a clear goal is more useful than a promise that CBT fixes everything. See CBT. [1], [4]

What should I do if progesterone days seem worse?

Tell your prescriber about the pattern and its effect on daily life. A short dated record can help review the complete regimen, but does not prove causation. Do not remove prescribed endometrial protection while continuing systemic estrogen without an agreed alternative if you have a uterus. Options must account for protection, tolerability and your medical history together. Significant mood deterioration also needs assessment on its own timetable. See tolerability, rather than copying another person's schedule. [2], [5]

Can a hormone blood test explain why I feel anxious?

A single result cannot establish that anxiety has a hormonal cause or select an HRT dose that will fix it. Menopause assessment depends on age, symptoms, medicines and history; routine hormone tests generally are not needed for typical menopause symptoms at 45 or over. Anxiety can coexist with the transition and deserves its own assessment when distressing. Describe the episodes and their impact rather than seeking a universal estrogen target. See assessment. [1], [2]

Does improved brain fog mean HRT is protecting my brain?

Symptom improvement and prevention of dementia are different outcomes. Better sleep or concentration matters, but does not demonstrate future disease prevention. The older WHI memory-study population and historical oral regimen also cannot directly answer a younger person's brain-fog question. NICE advises against offering HRT for dementia prevention. Persistent or progressive cognitive difficulties warrant clinical assessment regardless of hormone treatment. See cognition and the linked WHI guide for the relevant populations and outcomes. [1], [6]

Do I need to wait three months before asking for more help?

No. Three months is an ordinary menopause treatment review point, not a waiting rule for worsening mood, adverse effects or safety concerns. Ask how to contact the team earlier and who coordinates mental health follow-up. Depression care can have a different review schedule. If you feel in immediate danger of harming yourself or someone else, seek urgent local emergency or crisis care now. See tracking and follow-up and the opening safety advice. [1], [2]

Glossary

Terms used in assessment and care.

Perimenopause

The transition toward menopause, with changing ovarian hormone patterns and possible symptoms.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Vasomotor symptoms

Hot flashes and night sweats.

FSH

Follicle-stimulating hormone; interpretation depends on age, stage and medicines.

Depressive symptoms

Low mood or related symptoms; not by itself a diagnosis of a depressive disorder.

Depression

A clinical condition assessed through symptoms, duration, functioning and history.

Anxiety

Worry, fear or related symptoms that may need their own assessment when distressing.

Euthymic

Without a current depressed mood state at study entry in the trial described here.

CBT

Cognitive behavioural therapy, a structured psychological treatment.

CES-D

A depressive-symptom questionnaire; a study threshold is not identical to a clinical diagnosis.

Brain fog

An everyday description of concentration or memory difficulties, not a dementia diagnosis.

Dementia

A clinical syndrome of cognitive impairment; distinct from a passing word-finding difficulty.

Placebo

A comparison treatment without the studied active hormone intervention.

Randomization

Allocation by chance to study groups to help limit confounding.

Confounding

Another factor that can distort an apparent relationship between treatment and outcome.

Adverse effect

An unwanted effect potentially related to treatment; a diary alone does not establish its cause.

Indication

The condition or purpose for which a treatment is used.

Follow-up

Review of response, unwanted effects and the next treatment decision.

How was this guide researched?

Source selection and limits

Current NICE menopause recommendations and the relevant adult-depression recommendations were read together, with the original menopause CBT rationale. The full Gordon 2018 trial via PMC supplies the prevention population, outcome threshold, percentages and qualifications; its research progesterone schedule is not recommended here. BMS May 2026 original protection guidance was checked in this project. The WHIMS source was accessible as its original PubMed abstract only. Public opening text and accessible Mumsnet replies were refreshed, including benefit, partial response and unwanted effects, without copying personal histories or medical instructions. Practical preparation and diary suggestions are editorial. No treatment-response rate, universal hormone target or independent clinical review is invented.

This is an AI-assisted Doserly editorial guide checked October 3, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical record-keeping suggestions are editorial advice, not a validated diagnostic scale or clinical-monitoring system. Material new guidance, labels or safety information trigger earlier source review.

Sources